<DOC>
	<DOC>NCT02955498</DOC>
	<brief_summary>The purpose of this study is to assess the pharmacokinetic characteristics of olmesartan and S-amlodipine after single oral administration of Sevikar tab. 10/40mg, a combination formulation of olmesartan and amlodipine as reference drug and Lodivikar tab. 5/40mg, a combination formulation of olmesartan and S-amlodipine as test drug in healthy male adults. Additionally the safety and tolerability of two drugs will be evaluated.</brief_summary>
	<brief_title>Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male in the age of 2045 Body weight ≥ 55kg, IBW ± 20% Subject who sign on an informed consent form willingly Subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease Subject with known for hypersensitivity reaction to Samlodipine, amlodipine and olmesartan and dihydropyridine derivatives Clinically significant hypotension (SBP≤100mmHg, DBP≤60mmHg) or hypertension(SBP≥150mmHg, DBP≥95mmHg) when screening period Subject with known for history of disease or gastric surgery which affect on the absorption, Subject with any of the following conditions in laboratory test AST or ALT &gt; UNL (upper normal limit) x 1.5 Total bilirubin &gt; UNL x 1.5 Renal failure with CLcr &lt; 50mL/min calculated on CockcroftGault [CockcroftGault GFR = (140age) * (Wt in kg) / (72 *Cr)] Serum potassium &lt; 3.5 mEq/L or &gt; 5.5 mEq/L Continued excessive use of caffeine (caffeine &gt;five cups/day), alcohol(alcohol&gt;30g/day) and severe heavy smoker(cigarette &gt;10 cigarettes per day) Participation in any clinical investigation within 60days prior to study medication dosing Subject with whole blood donation within 60days, component blood donation within 30days prior to study medication dosing Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 28days prior to study medication dosing Use of any prescription medication including oriental medication within 14 days prior to study medication dosing or overthecounter medication within 7 days prior to study medication dosing Subject with mental illness or drug addiction Subject taking foods which affect on the absorption, distribution, metabolism or excretion of drug within 7days prior to study medication dosing Subject with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as nonresponding to request or instruction by investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>